ISB News

New Study Identifies Organ-Specific Biomarkers for Acute Liver Injury

ISB scientists recently published a study in the Journal of Proteome Research that presents results from a study on identifying organ-specific blood biomarkers for acute liver injury due to over-exposure to acetaminophen. From the summary:

3 Bullets:

  • Finding organ-specific blood biomarkers for disease that are clinically useful is challenging.
  • New study identifies organ-specific blood biomarkers for acute liver injury caused by over-exposure to acetaminophen.
  • ISB researchers use the powerful, targeted mass spectrometry approach of selected reaction monitoring (SRM) to identify proteins.

Adverse effects associated with therapeutic drugs are a serious health concern and a costly challenge for healthcare systems. Many drug-induced adverse effects target the liver due to their immediate exposure through first-pass pharmacokinetics and the liver’s active roles in metabolizing xenobiotics.

To assess probable injury to an organ, it is important to monitor biologic materials that originate exclusively or primarily in that organ, in this case, liver-enriched proteins. For decades, cellular integrity indicators, such as levels of the transaminases, alanine aminotransferase (ALT, GPT), and aspartate aminotransferase (AST, GOT) in serum, have been used to reflect liver injury. However, use of these enzymes as surrogate markers of liver injury is not ideal. Because they are ubiquitously expressed at similar levels in multiple organs, an interpretation of their change in levels in blood in response to a toxin can be complicated as a consequence of these enzymes originating from many tissues other than liver.

READ MORE….

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.